• NF 449: Evidence for Selective P2X1 Blockade

  2026-10-14

  NF 449 is supported by recombinant-receptor evidence as a highly potent antagonist of P2X1-containing channels, but its selectivity and platelet relevance depend on biological context. The key study does not by itself establish efficacy in native platelets, animal thrombosis, or clinical antithrombotic use.

• Sequential Mitochondrial Transplantation in IRI

  2026-10-13

  This ACS Nano study presents a preclinical strategy for myocardial ischemia-reperfusion injury that combines early local mitochondrial support with later systemic supplementation. Its findings are promising but remain limited by the condensed evidence available, absent quantitative outcomes, and uncertain translation to human care.

• Netrin-1 and Adipose Remodeling in Obesity

  2026-10-12

  A mouse study reports that adipose-derived Netrin-1 may hinder compensatory adipose remodeling during excess-calorie exposure by suppressing adipogenic differentiation through PPARγ and Wnt/β-catenin signaling. The findings are mechanistically suggestive but remain preclinical and do not establish a human treatment strategy.

• What the IEM-1925 Soman Study Shows

  2026-10-12

  A 2026 rat study evaluated IEM-1925 as a dual AMPA/NMDA glutamate-receptor antagonist after soman-induced status epilepticus. It reported improved survival, seizure control, hippocampal preservation and behavioral outcomes, but the findings are preclinical and should not be generalized to IEM 1460, human treatment or nerve-agent exposure outside the study context.

• Smurf1 and Cisplatin Sensitivity in Colorectal Cancer

  2026-10-11

  Guo and colleagues investigated whether Smurf1 expression influences colorectal cancer response to gemcitabine and Cisplatin (CDDP). Across HCT116 cell, cell-derived xenograft, and patient-derived xenograft models, reduced Smurf1 was associated with greater drug-related apoptosis and antitumor effects. The findings support Smurf1 as a preclinical chemosensitivity marker, but they do not establish clinical efficacy, patient selection criteria, or a treatment strategy.

• Annexin V-HF647/PI Kit for ESCC Apoptosis

  2026-10-10

  Explore how the Annexin V-HF647/PI Apoptosis Kit can support careful interpretation of apoptosis phenotypes in esophageal squamous cell carcinoma research, using the HOXC9–AKT/mTOR study as a framework for separating observed cell death from mechanistic inference.

• Deracoxib: Evidence in Canine Osteosarcoma

  2026-10-09

  Deracoxib is a selective COX-2 inhibitor with established relevance to veterinary pain and inflammation research, while its anticancer evidence remains primarily cell-based. This overview examines the strongest supplied study, compares its findings with catalog-level claims, and defines the limits of translating in-vitro cytotoxicity into clinical oncology conclusions.

• Gamma-Linolenic Acid: Evidence in Context

  2026-10-09

  A source-grounded overview of Gamma-linolenic acid (GLA), covering its proposed inflammatory mechanisms, evidence quality, interpretation of laboratory findings, clinical scope and key limitations. The supplied vaccine study concerns arachidonic acid rather than GLA, so it cannot establish a GLA benefit.

• Biomimetic Nanotherapy for Metastatic TNBC

  2026-10-08

  Cheng and colleagues developed a biomimetic nanoplatform that combines photothermal tumor ablation with immune remodeling for metastatic triple-negative breast cancer. The study is notable for integrating tumor-cell-membrane targeting, stimulus-responsive release, an immune adjuvant, and checkpoint-related peptide activity, while remaining preclinical and model-dependent.

• Methotrexate Beyond Mechanism: Translational Strategy

  2026-10-08

  Methotrexate is more than a DHFR inhibitor: its polyglutamate persistence, phase-dependent effects, and adenosine-linked immunomodulation create a translational opportunity—and a measurement challenge. This thought-leadership article connects mechanistic biology with biomimetic membrane models while defining the evidence boundaries researchers should respect.

• FGF10 and the Next Strategic Layer of CAR-M

  2026-10-07

  CAR-M therapy is moving from a cell-engineering question toward a systems-biology challenge: how can engineered macrophages remain active, selective, and compatible with tissue context? This analysis examines the 2026 in situ CAR-M study in hepatocellular carcinoma and positions Recombinant Human FGF10 as a hypothesis-generating tool for studying that broader translational landscape.

• Drosophila Keap1, Lamin, and Nuclear Architecture

  2026-10-07

  Carlson and colleagues identify a functional connection between Drosophila Keap1 and the B-type lamin lamin Dm0, linking xenobiotic-response signaling with nuclear lamina organization and heterochromatin distribution. The findings broaden the biological scope of Keap1 beyond transcriptional control of detoxification genes, while remaining dependent on evidence from a Drosophila developmental model.

• Heparin Sodium and Plant Nanovesicle Research

  2026-10-07

  Heparin sodium is an established glycosaminoglycan anticoagulant, while a 2025 version 1 preprint reports that Cistanche deserticola-derived exosome-like nanovesicles may enter Sertoli cells through heparan sulfate proteoglycan-associated biology. These topics overlap conceptually, but the published record does not show that heparin sodium was tested as a treatment, uptake enhancer, or validated mechanistic substitute in that nanovesicle model. The evidence supports cautious use of heparin as a conceptual comparator, not direct translational conclusions.

• Alcian Blue & Nuclear Fast Red Staining Kit: Evidence

  2026-10-06

  The Alcian Blue & Nuclear Fast Red Staining Kit, pH2.5 combines acid-mucin visualization with nuclear counterstaining for clearer interpretation of matrix-rich samples. This evidence-focused guide distinguishes biochemical staining signals from pre-analytical tissue-marking findings and defines appropriate research applications and limitations.

• CF10 and EdU Drive Telomere Attrition in CRC

  2026-10-05

  A 2026 NAR Molecular Medicine study identifies strong, model-dependent synergy between the fluoropyrimidine polymer CF10 and EdU in colorectal cancer cells. The evidence links enhanced EdU incorporation with DNA double-strand breaks, cell-cycle disruption, reduced telomere staining, and mitotic catastrophe, while also defining important limits on interpreting the findings as direct telomerase inhibition.

8628 records 1/576 page Next 12345 下5页 Last page